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ABSTRACT
The ex vivo expansion of hematopoietic stem cells (HSCs) for transplantation has
threefold importance: 1.) First, because of the rarity of stem cells there often isn’t a
sufficient supply obtainable from common sources for larger children and adults. 2.)
Secondly, patient morbidity and time to hematopoietic reconstitution following
myeloablative preconditioning is improved by administering a larger pool of HSCs. 3.)
Lastly, gene therapies for hematological diseases still require a robust supply of HSCs to
offset varying degrees of inefficiency in vector mediated transfection protocols. These
reasons, and others, have been an impetus for many discoveries made within four primary
subdivisions within the field of HSC expansion; culture media optimization,
hematopoietic gene regulation, development of small molecular compounds, and use of
induced pluripotent stem cells (iPSCs). This article is a review of the current trends in
HSC expansion methodology and posits that the majority of the singling mechanisms
involved can be explained by the collective contribution of activating and inhibitory gene
expression products interacting through regulatory homeostatic process mediated by HSC
sensing of key pathway dependent thresholds.
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CHAPTER 1.

INTRODUCTION

HSC Expansion
While our knowledge of hematopoietic stem cell (HSC) regulatory systems is
quickly becoming more advanced, the complex interplay between relevant signaling
pathways has made development of HSC expansion regimes a challenge. Seminal
accomplishments in overcoming HSC expansion difficulties have been achieved, albeit
marginally, by optimizing media through the use of a multitude of cytokine combinations
at very high doses or through the constitutive activation of key transcription factors and
genes. While these approaches have generated invaluable knowledge about HSC
regulatory mechanisms, they have not been overwhelmingly successful at providing
clinically significant quantities of HSCs for use in hematopoietic stem cell transplants
(HSCTs) without combining multiple sources. It is not lost on this author that hindsight
affords an easy view of the shortcomings surrounding any particular method of HSC
expansion, and that such discoveries carry great weight in our current understanding.
However, at some point our culmination of knowledge and rapidly developing
technology mandates that outmoded methods be challenged to quickly capture the
possibilities that loom before us. Simply, there are numerous examples of worthwhile
therapeutic developments that are producing markedly better HSC expansion than a halfdecade ago. It is this author’s contention that these methods should be appropriately
integrated for maximal HSC expansion if the ultimate goal is to produce clinical quality
stem cell treatments as quickly as possible so that patients as well as the science can
benefit from these forward-looking strategies.
Background
Hematological disorders are routinely treated through chemotherapeutic ablation
of the hematopoietic system and subsequent reconstitution with HSCTs. Currently, more
than 25,000 HSCTs are performed annually utilizing HSCs from bone marrow (BM),
umbilical cord blood (CB), and peripheral blood containing stem cells mobilized through
granulocyte colony-stimulating factor (G-CSF) stimulation. However, matching an
unrelated allogeneic donor with a recipient by human leukocyte antigen (HLA) can be
challenging due to the lack of diverse race and ethnic makeup contained within many
bone marrow registries.1 Even so, when a patient does meet the requirements to be
considered for a transplant, then the need to obtain as many HSCs as possible becomes
paramount because patient outcomes have been shown to be correlated with
administering a total nucleated cell (TNC) dose of greater than 3 x 107/kg.2 Moreover,
doses attaining a TNC of 5.2 x 107/kg conferred better outcomes further highlighting the
necessity for a robust means of obtaining the greatest amount of HSCs possible.3
Hematopoietic stem cell expansion for the purpose of reconstituting myeloablative
treated patients receiving HSCTs has been an important goal for blood therapeutics since
the pioneering work of Till and McCulloch in the 1960’s as well as Nobel laureate
Donnall Thomas’ research on blood transplants for treating leukemia in the 1970’s.4,5
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Myeloablative preconditioning of a diseased hematopoietic system before a HSCT can
reconstitute the space often compromises a patient’s immune system and leaves him
anemic. Only about .01% of whole bone marrow (WBM) is thought to contain
multipotent HSCs. There needs to be quick and robust means of reconstituting the BM
quickly so that the duration of morbidity is reduced. Inherent limitations to supplying
patients with sufficient numbers of HSCs are compounded by the rarity of stem cells
within the BM space as well as the multitude of signaling pathways that carefully
regulate their proliferation.
Expanding HSCs would be inordinately easier if they were all created equal.
Instead, HSCs are a heterogeneous mixture of cells that have been difficult to
characterize based upon cell surface marker expression.6 The heterogeneity of HSCs
within the bone marrow (BM) allows them to be divided into three main populations:
long-term self-renewing HSCs (LT-HSCs), short-term self-renewing HSCs (ST-HSCs)
and multipotent progenitors (MPPs). ST-HSCs and MPPs are only able to restore the
ablated hematopoietic system of a lethally irradiated mouse for up to four months, after
which failure of the hematopoietic system will occur. This being the case, much effort
has been spent trying to expand and maintain LT-HSCs, which can fully restore the
hematopoietic system of lethally irradiated BM when administered within a transplant.
When LT-HSCs and ST-HSCs are extracted from their niche, either through G-CSF
mobilized bone marrow or by bone marrow extraction, they can differentiate into MPPs
through the progressive loss of self-renewal ability, which includes concordant increases
in hematopoietic progenitor proliferation. Unless methods are in place to maintain HSC
self-renewal capacity within specialized culturing conditions, they will undergo apoptosis
or differentiate into progenitors, thereby jeopardizing their usefulness for conducting
HSCTs. Current methods of promoting HSC self-renewal in favor of differentiation can
be classified into four main categories: culturing conditions and factors (ex. hypoxia,
automated bioreactor culture feeding, SCF, TPO, IL-3, IL-6); regulatory pathways and
transcription factors (ex. HOXB4, Notch-1, Wnt, SALL4); small molecule therapeutics
(ex. AhR antagonists, GSK-3β inhibitors), and through hematopoietic lineage
commitment of induced pluripotent stem cells (iPSCs).
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CHAPTER 2.

MODELING PATHWAY SPECIFIC THRESHOLDS

Many of the methods this article enumerates involve exogenous manipulations of
the steady-state of HSC gene expression for various relevant signaling pathways.
Granted, little detail is known about how the steady-state behaves under homeostatic
processes for these pathways within the BM niche or how it changes under physiological
stress. Moreover, when utilizing HSC expansion adjuvants, the interplay between genes
that have beneficial effects on HSC expansion and the concordant increases in negative
feedback regulatory genes can be extremely complex. Evidence of this complexity is
documented within the literature as underwhelming HSC expansion and blocks in
progenitor populations when constitutively expressed genes or over stimulation of
important HSC regulatory pathways occurs.7–9 Paradoxically, moderation can stray too
far in the opposite direction, failing to achieve adequate pathway stimulation. However,
despite this level of complexity, optimal pathway stimulation is often achieved by
promoting key gene products whose expression enhances expansion capacity. These
groups of genes can be described for every repeating interval of time (t) within a single
hematopoietic stem cell through hypothetical microarray analysis, and taking repeated
snapshots of gene expression from the moment of administering a single targeted
adjuvant through its duration. The collective continuum of upregulated and downregulated genes can be placed into three broad categories for a particular point in time as:
1.) Activating (A) genes that maintain quiescence, deter differentiation, and promote selfrenewal. 2.) Inhibitory (I) genes that serve a negative feedback role and ameliorate the
effects of the expansion promoting set. 3.) And null (N) genes that are up or down
regulated, but collectively and individually do not have any measurable direct or indirect
impact on HSC expansion, and can therefore be ignored.
The collective interaction between A and I determines whether a particular
stimulus or environmental cue at a particular time will promote expansion or favor
differentiation. While it might be useful to imagine that for every interval of time (t) each
upregulated or down regulated gene within A could be scored on its individual ability to
expand HSCs, but this would be of little practical use because it would ignore the
collective interactions between complementary genes. Therefore the interaction of A with
I over a period of time can be represented by the sum of two logarithmic curves. The
positive A curve represents the initial stimulation events and the subsequent increase in
gene expression that favors maintaining stem cell properties. The negative value of the I
curve, which subtracts from the A curve, represents the delayed response of the genes
involved in ameliorating the initial signaling wave through negative-feedback. The
smoothed out sum of these two curves (A+ I) forms a sinusoidal biphasic response with
potential (depending upon the signaling pathway) for repeating when the stimulation of a
HSC pathway is strong enough to exceed the pathway specific threshold that induces
upregulation of negative-feedback.
It is posited that stimulation that induces signaling, but does not cross the
negative-feedback threshold range can induce expansion promoting gene expression,
while optimally maintaining genes associated with negative-feedback at low homeostatic
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levels. Preventing sharp biphasic swings between stimulation and feedback inhibition
should therefore be the goal when using HSC expansion promoting adjuvants. To this
extent automated culture feeding and dilution mechanisms can likely achieve the control
necessary to mitigate excessive signaling crests and troughs. Examples of this reasoning
can be observed within the Wnt and Notch pathways, which have been shown to respond
in a biphasic manner to pathway stimulation.10,11 It is hypothesized that this biphasic
response is mediated by two pathway specific thresholds. The first threshold, T1, is
defined by the level of pathway stimulation needed to upregulate genes associated with
negative-feedback control from a particular stimulus beyond baseline. A high T1, which
is believed to occur in Hif-1α mediated hypoxia signaling, allows stronger environmental
stimulation before failure occurs (Figure 1-1). Conversely, canonical Wnt signaling
within HSCs is posited to have a low T1, mandating moderate signaling regulation to
achieve optimal expansion. The second threshold, T2, is defined by the range that the
collective effects of negative-feedback genes are able to reduce the expansion capabilities
by at least 50% of optimal max signaling. T2 corresponds to the sensitivity of the pathway
to its own negative-feedback. A low T2 will mean that a pathway needs less negativefeedback gene expression over baseline to ameliorate expansion inducing gene
expression. Likewise, a high T2 means that the pathway stimulation has a greater range
and likely requires less stringent regulation.
An important factor in determining the period of the biphasic response to
stimulation is the time between T1 being reached by A and when T2 is crossed by I. This
period determining interval (P) along with the rate and potency of negative-feedback
inhibition will determine the decay of the stimulation. If the amplitude of a biphasic
response isn’t able to be compressed by adjusting the concentration of the signaling
stimulus, so that the stimulatory signal can be maintained at a more steady level instead
of fluctuating, then decreasing the best-fit slope of the falling wave will provide extended
period of expansion promoting signaling. To this extent, the falling portion of the
stimulatory wave corresponds to increasing permissiveness of HSCs to expansion
inducing signaling. An example would be providing exogenous Notch signaling within
HSC culture media to maintain permissiveness to concurrent canonical Wnt singling,
which has been shown to promote expansion.12 By the same notion, delaying the rising
slope of I, through the potential use of selective inhibitors or siRNA should permit a
longer duration HSC promoting signal.
To this end, the synergistic effects of all expansion promoting genes on one
another under the effects of a single targeted compound need to be quantitated. This
should be done under the same stimulus for both A and I. While current technological
limitations bar such comprehensive measurements, examples of ongoing optimization
using induction-coupled mass spectrometry indicate potential access to comprehensive
data across multiple singling pathways.13
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Figure 1-1. Location of theoretical regulatory gene thresholds T1 and T2 for HIF-1
mediated hypoxia
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CHAPTER 3.

OPTMIZING MEDIA CONDITIONS

HSC cytokines have been optimized by different labs but have not worked well at
expanding HSC cultures to the levels required for HSCT.14–16 While the administration of
such cytokines is necessary for maintaining HSCs, they have not been shown to impart
marked therapeutic potential on their own, necessitating other complimentary signals.14
Despite further identification of HSC culturing media factors and a greater understanding
of the signaling mechanisms promoting HSC expansion, none of the cytokine-based
culturing strategies has been successful at deterring cell cycling, apoptosis, disrupted
bone marrow homing, or HSC differentiation.17
Automated Feeding Systems
Advances that attempt to rectify the issues with cytokine treatments have involved
automated culture-feeding systems. It has been known that growing HSC cultures
produce secreted factors that, if not quenched have an overall inhibitory effect upon
growing cultures.18 Recently, efforts have been made to improve ex vivo culturing
conditions to better favor self-renewal by using automated feeding methods to limit the
effects of inhibitory molecules (TGF-β, MCP-1, MIP-1α, MIP-1β, and IP-10) that
accumulate within growing HSC cultures.19–22 By continually adding media at an
optimized rate, an automated feeding method is reported to dilute inhibitory factors
below a threshold so that the negative feedback effects on HSC expansion are sufficiently
reduced. To date, this method has led to an 80-fold increase in CD34+ cells and an 11fold increase in blood stem cells, which was better than simple media exchange of the
cultures.23
The fed-batch method of media delivery that Csaazar et al. developed continually
increases the volume of cultures so as to optimally expand cells and dilute away the
inhibitory factors, which was better than perfusion driven media exchanges that maintain
the same volume of the cultures by removing an equal amount of media that is added.
The report claims that the fed-batch method simplifies HSC culturing conditions by
eliminating the need for dosing the cultures with multiple compounds that independently
target and inhibit the negative feedback ligands produced in culture. However, this
benefit is offset by the increased complexity over basic culturing methods required with
an automated feeding system. Moreover, the authors found that the fed-batch method
works synergistically when combined with small molecular factors that have
demonstrated successful HSC expansion capabilities, suggesting that the optimal means
of expanding HSCs involves combining fed-batch with small molecular therapeutics and
cytokines. For instance, both the small molecule aryl hydrocarbon receptor (AhR)
antagonist StemRegenin (SR1) and the soluble TAT-HOXB4 were shown to expand
HSCs more robustly when the inhibitory molecules were diluted away using the fedbatch culture feeding system.23
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Recapitulating the Bone Marrow Niche: Hypoxia
Strategies for ex vivo HSC expansion often rely on providing the essential HSC
factors in the optimal stoichiometric ratios within the confines of a culture dish in order
to promote robust self-renewal and survival. While efforts to understand and distill the
multitude of intrinsic and extrinsic cues that control HSC biology have made great
progress, determining what factors get labeled essential for ex vivo expansion can come
down to a mixture of targeted discovery, serendipity and trial and error. So what role
does providing hypoxic cues play in establishing an analogous physiological environment
for HSC expansion? The answer isn’t clear; however, the importance of in vivo low
partial pressure oxygen (pO2) for maintenance of HSC quiescence and reduced
dependence upon mitochondrial oxidative phosphorylation is certain.24
Under normal physiological conditions within the bone marrow, HSCs have been
found to be concentrated in the less vascular endosteum regions of trabecular bone,
regions that carry an oxygen tension between .1 to 4%.25 Within this hypoxic BM niche,
HSCs have adapted to the low pO2 by utilizing glycolysis as the primary source of ATP
instead of mitochondrial oxidative phosphorylation. Cellular adaption to hypoxia through
Hif-1α-induced increases in vascular endothelial growth factor (VEGF) and Tie-1 have
been found to play a role in maintaining HSC quiescence.26 There is also evidence that
hypoxia-induced stabilization of Hif-1α plays a regulatory role within the canonical Wnt
pathway of embryonic stem (ES) and neural stem cells that leads to β-catenin
accumulation and downstream interaction with Lef/Tcf, which needs further investigation
to determine if a similar function occurs within HSCs.27
While translational processing of Hif-1α is thoroughly understood, much is still
unknown about regulation at the transcriptional level. In 2010, Hif-1α was shown by
Simsek et al. to be induced by Meis1, a member of the Hox gene family.24 Interestingly
Meis1 was found to be expressed in 96% of LT-HSCs while only 1.4% of WBM had
expression. Moreover, Meis1, through a consensus binding sequence at the first intron of
Hif-1α, plays an important role in Hif-1α preservation even in the absence of hypoxic
cues. The ability of Meis1 to prevent Hif-1α degradation under normoxic conditions,
along with diminishing Meis1 levels coinciding with increasing levels of HSC
differentiation, suggests that creating a conditionally activated Meis1 could be used to
help maintain HSC quiescence. However, there is evidence that such efforts won’t work
or would need precise regulation because very high levels of Hif-1α expression, which a
constitutively active Meis1 might induce, can lead to impairment of transplantation
capacity.9
Additional observations from Eliasson et al.28 were consistent with an
independent study from Takubo et al.9 that found high-level expression of Hif-1α
accomplished through either a constitutively active Hif-1α, culture treatment with HIFstabilizing agent FG-4497, or through deletion of the Von Hippel-Lindau (VHL) E3 that
mediates Hif-1α degradation, ultimately led to a reduction in HSC reconstituting
ability.9,28,29 This shouldn’t dissuade investigation of Meis1 for HSC expansion purposes
because markedly different dosage-dependent outcomes exist within other HSC-relevant
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signaling pathways (canonical Wnt, Notch-1) wherein a narrow range of stimulation
provides optimal HSC expansion, and activation straying too far outside these cellulardependent ranges can lead to anemic HSC expansion or outright failure.30 These common
HSC dosage-dependent sensitivities highlight the usefulness of employing a gradient of
expression levels such as that used by Luis et al. for determining optimal HSC expansion
ranges within the canonical Wnt pathway.30
Concurrent with HIF induction, hypoxic HSC culturing conditions have been
shown to be advantageous by reducing reactive oxygen species (ROS) generation and
preventing a quiescent to cycling influx.28,31 Under normoxic conditions of 20% O2,
ROS generation increases DNA damage as well as activates p38 MAPK, which is known
to adversely affect HSC longevity.32,33 Hypoxic environments, such as those of the BM
niche, have been shown to protect LT-HSCs from ROS-induced DNA damage and
preserve LT-HSC quiescence and multilineage repopulation ability.28 However, it should
not be overlooked that ROS have important signaling functions throughout the cell that
include inducing differentiation. In line with the signaling function of ROS is the finding
that they have been found to play a synergistic role with thrombopoietin (TPO) and other
HSC cytokines to promote HIF-1 mediated quiescence under normoxic conditions.34 This
suggests that the decision between utilizing hypoxic or normoxic culturing conditions can
be muddled due to the complexity of interactions under differing cytokine combinations,
which might very well obfuscate the utility for recapitulating the oxygen tension found
within the BM niche.
That being said, hypoxic conditions for ex vivo culturing have demonstrated
increased repopulating capacity and HSC numbers, despite reductions in total cell
numbers when contrasted with normoxic conditions.26,28,35 Long-term FLT3- CD34- LinSca-1+c-Kit+ (LSK) cells, when cultured under hypoxic conditions, had total cell numbers
that were significantly reduced in comparison to normoxia.28 However, these
observations were shown to be due to decreases in progenitor proliferation and an efflux
of cells from the cell cycle into G0 due in part to upregulation of cyclin-dependent kinase
inhibitor (CDKI) genes p21cip1, p27Kip1, and p57Kip2 within the hypoxic LSK
population. Moreover, fewer hypoxic LSK cells were required to reconstitute lethally
irradiated mice to the same degree as normoxic cultures, suggesting that despite both
hypoxic and normoxic conditions’ ability to preserve HSC populations; LT-HSCs are
expanded more robustly under hypoxic conditions.
While using lowered oxygen tensions instead of normal atmospheric oxygen
levels might be of benefit, it is known that certain stem cell factors such as
thrombopoietin (TPO) can scavenge and inactivate ROS, which most likely provides
some of the benefits of hypoxia while maintaining the cultures under non-hypoxic
conditions.36 It is hypothesized that quenching ROS formation using antioxidant culturing
adjuvants, such as glutathione (GSH) and ascorbic acid 2-phosphate (AA2P), under
normoxic conditions might preserve HSC multipotency and retard differentiation in
human mobilized peripheral blood (mPB) slated for transplant.37 Yet to be identified is
whether such additions will make significant improvements in HSC maintenance, and it
is assumed that such treatments would supplement more potent forms of HSC expansion
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instead of being used in isolation. Paradoxically, quenching ROS production within HSC
cultures to extremely low levels could have adverse effects on expansion efforts. This is
because findings in 2008 suggest that TPO stabilizes HIF-1α by generating mitochondrial
ROS, that when quenched by electron transport chain (ETC) inhibitors or potent ROS
scavengers mitigated downstream Hif-1α expression.34 Similar findings have been
observed for proliferation-inducing cytokines such as stem cell factor (SCF), IL-3,
erythropoietin (Epo) and granulocyte colony-stimulating factor (G-CSF), all of which
generate and use ROS to promote proliferation.38–40 These are not incongruent findings,
per se, but most likely highlight the multifunctional roles that cytokines and ROS can
play within different cellular contexts.
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CHAPTER 4.

GENES AND TRANSCRIPTION FACTORS
Hox Genes and HSC Expansion

Hox genes that were first implicated in embryonic development and structural
patterning are now known to play a function not just in embryonic cells, but also in
somatic cells, such as those of the hematopoietic system.41 Among the Hox genes, which
compose the homeobox gene family, are four clusters of highly conserved transcription
factors (TF) that are classified as A, B, C, and D and have been found to have
overlapping roles among the clusters.42 Of the 39 Hox mammalian genes, 16 are
transcribed during hematopoiesis and encode TFs that are involved in regulating selfrenewal and differentiation. Certain pivotal discoveries have shown that species of the A
and B clusters are highly enriched in primitive hematopoietic subpopulations and play a
positive regulatory role in HSC self-renewal.43
HoxB4 is particularly enriched within the early hematopoietic subpopulations
and, when overexpressed in murine bone marrow (BM) has led to a 50-fold increase in
numbers of competitive repopulating unit (CRU). Ex vivo expansion of HoxB4transduced cells resulted in a 40-fold increase in HSC compared to starting numbers after
14 days of culturing and over 1000-fold increase when compared to controls.44 Moreover,
retrovirally transduced HoxB4-expanded murine HSCs maintained lymphoid and
myeloid repopulating potential without incurring blocks in development. Successful
efforts have been made to improve upon the retroviral transduction of HoxB4 by
concurrently suppressing expression of Hox cofactor PBx1 as well as generating a
NUP98 nucleoporine gene fusion with HoxB4 and HoxA10.45 With respect to the NUP98
fusion proteins, there was a 300-fold increase in CRUs among the NUP98-HoxB4
version and 2000-fold increase with the NUP98-HoxA10 version.
Furthermore, strategies have been pursued that remove the need for retroviral
transduction, such as recombinant TAT-HoxB4 fusion using the transactivating protein
(TAT) of HIV to permit protein delivery through the cell membrane. Use of the
transduction-free TAT-HoxB4 protein for four days on ex vivo murine HSC cultures led
to 6-fold increases over starting HSC numbers and upwards of 20-fold increases over
control cultures.46 However, problems have been reported with high ectopic expression of
HoxB4 in human retrovirally transduced cord blood (CB) CD34+ cells, causing a
presumptive block in myeloerythroid progenitor differentiation while promoting an in
vivo growth advantage of primitive CD34+ populations.47 It has been suggested that there
isn’t a complete block, but instead a delay in differentiation commitment that is
potentially due to a dosage-dependent response, wherein an upper threshold, when
crossed, increases myeloerythroid abnormalities and within an undetermined range
optimal HSC expansion occurs without skewing production of certain progenitor
subpopulations.48,49 Means of addressing the commitment delay encountered by
constitutively high expression of HoxB4 have used inducible systems such as fusion of
HoxB4 with tamoxifen responsive oestrogen receptor serving as a way to eliminate
exogenous HoxB4 expression after expansion has occurred.50 Current studies are using
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such systems to investigate HoxB4 target gene expression and reaction kinetics necessary
for clinically relevant HSC expansion.
Two Routes on the Wnt Pathway
Maintenance of HSC self-renewal and inhibition of differentiation is known to
depend upon the presence of the canonical Wnt signaling pathway, which has received
focused research efforts.51,52 While there are other noncanonical Wnt pathways, namely
the planar cell polarity (PCP) and Wnt-Ca2+ pathway, neither directly promotes β-catenin
accumulation, which has been shown to play an important role in HSC self-renewal.51
Despite the lack of direct induction of β-catenin within the noncanonical
pathways, recent research has found that in vivo Wnt signaling through the noncanonical
pathways maintains LT-HSC quiescence within the BM niche populated by N-cadherin
positive osteoblasts (N-cad+OBs).53 Sugimura et al. report that N-cad+OBs within the BM
microenvironment interact with HSCs expressing Flamingo (Fmi) at the N-cad+OB
interface, which hydrophobically recruits the noncanonical Wnt receptor Frizzled 8 (Fz8)
to maintain quiescence. This localized noncanonical Wnt signaling, which antagonizes
canonical Wnt signaling, occurs predominately under homeostatic processes, but under
physiological stress, such as when fluorouracil (5FU) is administered for myeloablative
purposes, dynamic changes occur in the Wnt ligands of N-cad+OBs, leading to a shift in
increased canonical Wnt signaling due to loss of the antagonistic actions of the
noncanonical Wnt pathway.53 These observations suggest that noncanonical and
canonical Wnt signaling within the BM microenvironment work in opposition to balance
between HSC quiescence and proliferation.
The canonical wingless-type (Wnt) pathway consists of secreted palmitoylated
morphogens (Wnt3a) that bind the Frizzled family of receptors along with lipoprotein
receptor-related proteins 5 and 6 (LRP-5/6) and prevent ubiquitin-driven degradation of
β-catenin.54 Upon canonical Wnt pathway stimulation, glycogen synthase kinase (Gsk3β) phosphorylation of β-catenin is prevented, thereby promoting accumulation of βcatenin, which is imported into the nucleus where it can interact with T-cell transcription
factor (Tcf)/lymphocyte-enhancer binding factor (Lef) family to induce changes in target
gene expression. Concomitant with a whole host of Wnt-induced gene changes are
notable increases in HoxB4 and Notch1 expression, which have been shown to promote
self-renewal and likely play a role in the increased self-renewal capacity of Wntstimulated HSCs.44,55 As of this writing, expansion through canonical Wnt stimulation
has led to an 8-80 fold expansion in functional HSC numbers.51 Despite these
achievements, apparently incongruous results within the field have made HSC expansion
using canonical Wnt stimulation unclear.56 In several papers there has been
demonstration of exhaustion and blocks in myeloid differentiation within the HSC pool
following constitutive expression of stabilized forms of β-catenin7,57 whereas other
reports from different labs have shown enhancement of HSC function and
maintenance.51,54,58 A complete understanding of such inconsistencies will likely need
further research; however, it does appear likely that some of the inconsistencies can be
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attributed to differences in degree of Wnt pathway stimulation.30 Recent work by Luis et
al. used five different mutations in the adenomatous polyposis coli (APC) gene to
generate a gradient of in vivo Wnt signaling to show how intermediate levels of Wnt
stimulation led to increased myeloid differentiation potential and clonogenicity, whereas
only mildly increased Wnt signaling led to enhancement of HSC repopulation capacity.30
Notably, higher levels of Wnt pathway activation led to total failure of repopulation
capacity and were supported by a strong reduction of CFU colonies in methylcellulose
assays. Reductions in HoxB4 and Cdkn1a (p21) gene expression were also observed with
concomitant increases in Wnt stimulation, extending the evidence that optimal
maintenance of HSC self-renewal capacity is achieved through minimal canonical Wnt
stimulation.30 It is possible that low-dose Wnt stimulation may smooth out a sharp
biphasic response and thereby may limit exaggerated expression of negative regulators
such as Dickkopf-related protein 1 (DKK1).52,59 While some studies have shown
constitutively high Wnt activation to be beneficial in HSC expansion, it now appears that
regimented Wnt signaling offers the best HSC expansion outcomes.51,57
Achieving optimal levels of Wnt stimulation in a dynamic system can be
challenging; however, small molecular compounds that can be removed facilitate a level
of control that can be very useful for ex vivo expansion. Targeting Gsk-3β, which
functions as a hub for crosstalk among many other signaling pathways, doesn’t indicate
precise Wnt stimulation. This is because preservation of cytoplasmic β-catenin is one of
the primary means of changing target gene expression for the canonical Wnt, Hedgehog,
and Notch signaling pathways.60 Overlap of signaling mechanisms and indirect
regulatory feedback by downstream target genes can make it challenging to tease apart
the exact mechanism of HSC expansion drugs.
Regardless, most small molecule inhibitors of Gsk-3β attributed to the Wnt
pathway affect the ATP binding pocket, thereby preventing phosphorylation of β-catenin
on Thr41, Ser37, and Ser33.61 Several constituents of Tyrian purple, a dye produced from
mollusks, have been successfully tested for their selective ability to inhibit Gsk-3β and
expand the HSC pool through preventing β-catenin degradation.62 Chemical
modifications to these compounds, in particular, 6-bromoindirubin-3’-oxime (BIO), a
synthetic indirubin analog which is readily cell permeable, have shown a modest ability
to promote HSC expansion and prevent loss of HSCs when grown in culture.63 However,
recent insights suggest that Wnt stimulation alone isn’t sufficient to expand HSC ex vivo.
Notch signaling appears integral to regulating HSC permissiveness to Wnt induced selfrenewal. This interdependence upon multiple signaling pathways is likely common and
will necessitate expanding our continued understanding of HSC biology to connect oncedisparate pathways for development of better treatments.
Relevancy of SALL4
The zinc-finger transcription factor, SALL4 functions as a regulator of embryonic
stem (ES) cell pluripotency through Oct4 and Nanog and has been recognized for its
connections between leukemia and self-renewal in HSCs.64 Recent investigations of
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SALL4 HSC expansion properties have used lentiviral transduction to constitutively
express two isoforms (SALL4A, SALL4B) in human bone marrow (BM) CD34+ cells
which produced a 130-fold expansion of the CD34+/CD38- population after 7 days while
cultured in cytokines (SCF, TPO, Flt-3L).65 Extending the culturing time to 14 days led
to a 368-fold and 384-fold increase for SALL4A and SALL4B isoforms respectively,
with further increases in culturing leading to over 10,000-fold expansion. However, it
appears that SALL4 expansion is cytokine dependent and limiting levels of SCF and TPO
impacted SALL4 HSC expansion capabilities. An effort to test a more clinically relevant
means of using SALL4 without transducing cells led to the production of a cellpermeable fusion SALL4B-TAT protein. When SALL4B-TAT was administered at
200nM twice daily for four days to human CD34+ cells, it showed a modest 10-fold
expansion. The authors noted that further optimization will ultimately be necessary to
achieve more robust in vitro HSC expansion with the SALL4-TAT fusion protein. These
future optimizations will be important because the possibility exists for the latent
development of leukemia when transduction is used to achieve a constitutively active
SALL4.66
Relevancy of the Gatekeeper Notch
The Notch signaling pathway is an evolutionary conserved mechanism involved
in development and cell-fate specification along with regulatory functions that have been
identified in a multitude of stem cell systems.67 While there are four type I receptors
(Notch-1, -2, -3, and -4) with extracellular domains that can interact with a neighboring
cell’s membrane-bound ligands (Delta1, -3, -4, Jagged1, -2), determination of which
Notch receptor-ligand interactions are most efficacious within HSCs at promoting ex vivo
expansion is still ongoing.11 Mechanistically it is clear, however, that Notch receptorligand interactions between HSCs and HSCs-to-stromal cells (adipocytes, endothelial
cells, macrophages and fibroblast) within the BM niche precipitate Notch pathway
activation. This induces TACE and γ-secretase mediated proteolytic cleavage of the
Notch intracellular domain (NCID), freeing it to translocate into the nucleus whereupon it
can interact with the transcription repressor CBF-1 and upregulate Notch target genes.
Elucidation of particular target genes that have been found to have significant roles in
maintaining HSC quiescence is still ongoing, but the Hes family of genes along with
GATA-2 is notable.68
Relevance of the Notch signaling pathway to hematopoietic tissues was first made
when Milner et al. identified Tan-1, a Notch homologue, within human Lin-CD34+ BM
cells based upon shared consensus sequences within other Notch homologues.69 Notch
activity within the hematopoietic system was further supported through the identification
of increased reconstitution ability when soluble human Jagged-1 was administered to
HSC cultures by Karanu et al.70 Furthermore, it was found that signaling between HSCs
expressing Notch-1 and BM stromal cells expressing Jagged-1 led to inhibition of HSC
differentiation, which was successfully abrogated through inhibition of γ-secretase
mediated Notch activation.71,72 Once relevance of Notch signaling was established within
the hematopoietic system, further investigations were conducted into HSC expansion
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using various forms of Notch signaling, including Notch-2.73 Within murine models, it
was conclusively shown that constitutively active expression of the intracellular domain
of Notch-1 (IDN1) within HSCs resulted in cytokine-dependent immortalization that
permitted both myeloid and lymphoid lineage differentiation.55 Despite moderate success
of promoting Notch-mediated increases in HSC progenitors within murine models,
successes within human HSCs initially proved to be hit or miss. In 2007, Chadwick et al.
reported that when human umbilical cord blood CD34+ cells were transduced with a
constitutively activated form of Notch, it led to unexpected altered cell-cycle kinetics,
resulting in apoptotic reductions in the absolute number of CD34+ cells.8 These
observations are in line with other reports corroborating altered cell cycle kinetics when a
constitutively active form of Notch is used.74
Interestingly, no impairment of HSC self-renewal or differentiation was observed
when a Cre-LoxP mediated conditional inactivation of Jagged1 within BM stromal cells
was performed.75 These findings led Mancini et al. to conclude that Notch-1-Jagged-1
signaling is dispensable for human HSC self-renewal and differentiation under
physiological conditions. Further investigations will likely need to be performed to
ascertain whether other Notch pathway paralogs with overlapping functionality
compensated for the conditional knock out of Notch-1-Jagged-1 signaling. In light of the
dispensable nature of certain Notch signaling pathways in vivo it is interesting to see
marked success when an immobilized instead of soluble Delta-1 was used within
CD34+CD38- human cord blood cultures.76 Ohish et al. from the Bernstein lab
demonstrated that an immobilized Delta-1 was able to provide upwards of 100-fold
increase in the CD34+ cell population relative to controls.76 This observations led to the
publication of a 2010 phase I clinical study by Delaney et al. that successfully
demonstrated ex vivo Notch activation can be used to increase the number of HSCs and
progenitors while rapidly reconstituting myeloid engraftment in patients receiving
HSCTs.77 This is noteworthy because studies that had previously used soluble Notch
ligands within their investigations potentially did not induce endocytosis of the Notch
receptor-ligand complex necessary for pathway activation.78 Within the same lab, a
dosage dependent effect was observed for immobilized Delta-1 ligand stimulation of the
Notch pathway.79 In that study, lower levels of immobilized Delta-1 led to increased
CD34+ precursors, whereas higher levels were associated with apoptosis and inhibition of
myeloid differentiation. Moreover, lethally irradiated NOD/SCID mice ability to
reconstitute using CD34+ cells was better when lower Delta-1 densities were used.
It bears noting that these dosage-dependent Notch findings are similar to recent
discoveries made within the canonical Wnt pathway.30 Within the Wnt pathway,
relatively minimal stimulation provided better HSC expansion than higher doses did.
While the level of stimulation is important, the bigger picture is that determining the
optimal concentration range for HSC expansion regimens is critical. In fact, studies
utilizing a constitutively activated Notch or Wnt, while providing important data, haven’t
achieved ideal HSC expansion levels.
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What would be the outcome if optimal levels of selected signaling pathways were
determined and used simultaneously? A more advanced understanding of the complex
interplay is finally facilitating better optimization. For instance, it has been known that
canonical Wnt stimulation promotes self-renewal; however, it has now been found that
Notch plays an essential gatekeeper function that controls the Wnt pathway’s ability to
promote self-renewal.12 Interestingly, as Notch stimulation was inhibited, canonical Wnt
stimulation’s self-renewal properties were diminished and led to increasing rates of
differentiation. The integration of these two pathways fits our current understanding of
the BM niche because increasing levels of HSC differentiation show concordant drops in
Notch signaling. However, it is too early to determine whether differentiation itself leads
to lowered Notch signaling or whether decreases in Notch expression precede
differentiation events leading to the self-renewal effects of Wnt driving further
differentiation. Regardless, this study has implications outside understanding the
physiology of the BM niche because it can be used for better promoting the self-renewal
properties of small molecular therapeutics, such as GSK-3β inhibitors, and further
optimization efforts regarding optimal HSC density within starter cultures. While, it had
been known that high starting HSC cell densities are necessary within cultures to prevent
HSCs from prematurely differentiating, it is now assumed that high cellular densities
provide greater HSC-to-HSC Notch signaling that maintains HSC permissiveness to
concomitant Wnt self-renewal cures. It still remains to be seen exactly how other
signaling pathways integrate with one another within the HSC niche, but elucidation of
such interactions will improve upon and possibly lead to the development of new ex vivo
expansion techniques.
Furthermore, just has been observed in the Wnt pathway, Notch stimulation leads
to the upregulation of genes that have a negative feedback regulatory roles.80 For the
canonical Wnt pathway within ES cells, it was shown that a slow ramping on and off,
biphasic response was typical.10 It is possible that the biphasic response described for the
Wnt pathway might very well be truncation of a proposed oscillation model within neural
stem cells that has yet to be applied to HSCs.68,81 Nonetheless, the oscillation model is
interesting because HSCs need to function in two primary roles: self-renewal of LTHSCs and proliferation of progenitors. However, governing between these two roles
during homeostasis at the cellular level is relatively slow. The cellular cycling likely
belies a much more dynamic oscillating response that actively balances between
homeostasis and promoting proliferation under physical duress. More detailed single-cell
analysis will provide better insights into whether the oscillation model applies to HSCs. If
it does, then the information gleaned from such studies will enable better control of the
both the Notch and Wnt pathways.
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CHAPTER 5.

HSC MOLECULAR THERAPIES

Development of small-molecule compounds to alter existing signaling pathways
in order to induce HSC expansion has been of interest to researchers since the
identification of the first HSC factors. The ability to expand stem cells with an easily
administered adjuvant is particularly tantalizing because it can be withdrawn from the
culture relatively easily. Moreover, challenges faced by purifying proteins and mitigating
risks associated with vector-mediated gene integration approaches can make smallmolecule development appear tantalizing.82 Of course, small-molecule development has
its own set of hurdles that can necessitate screens of large chemical libraries, which are
often difficult or costly to access. However, advances in cheminformatics have permitted
in silico screening of large virtual chemical libraries, which enable target genes to be
computationally docked with databases of millions of small molecular compounds for
reduced lead-development costs.83 Regardless of how they are discovered, the following
efforts have led to chemical compounds that can induce HSC self-renewal, control
lineage commitment of progenitors, and revert linage-committed cells back to
multipotent states. Some of the primary means of facilitating HSC expansion include, but
are not limited to, canonical Wnt stimulation, AhR antagonism, Notch-1 stimulation,
chromatin modification, and copper chelation. While each of these has demonstrated its
own measure of success at HSC expansion, StemRegenin (SR1) has come the closest so
far of achieving the idealized goal of a single molecular compound that robustly expands
HSCs.84 This does not diminish the usefulness of other molecular compounds or
pathways, but highlights the challenge associated with finding a single compound that
can achieve expansion in a highly regulated and complex process.
The Aryl Hydrocarbon Receptor Success Story
The aryl hydrocarbon receptor (AhR) is a basic-helix-loop-helix (bHLH)
transcription factor that is involved in metabolizing xenobiotics and belongs to the PAS
(Per-ARNT-Sim) superfamily, which includes genes (Hif-1α) that play a role in cellular
sensing of hypoxia and oxidation-reduction status.85 The function of AhR in
hematopoiesis is not fully understood, but it is thought that one of its roles is as a
negative regulator of hematopoiesis by relaxing quiescence constraints and promoting
HSC proliferation when AhR is ablated or under the influence of an antagonist.85,86
Searches for endogenous AhR ligands that function to regulate hematopoiesis have not
yielded any tangible leads; however, studies have shown that exogenous constitutive
activation of AhR by the endocrine toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
leads to a 4-fold expansion of HSC numbers, albeit with a diminished long-term
repopulation capacity.87 In 2010, Boitanio et al. performed a confocal microscopy-aided
screen of 100,000 heterocyclic compounds for changes in human mobilized peripheral
blood (mPB) cell surface marker expression of CD34 and CD133 after ex vivo culture for
five days.84 StemRegenin1 (SR1) is one of the more successful purine analogs that were
identified to function as an antagonist of AhR, which was verified by reversibly blocking
with TCDD. Furthermore, SR1 went on to expand primary human CD34+ cells 73-fold
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after culturing with cytokines (TPO, SCF, FLT3, IL-6) for 3 weeks, which has been the
most successful ex vivo HSC expansion method to date, save the >10,000-fold monthlong expansion reported in the Aguila et al. SALL4 study.65,84
However, failure of the SR1 heterocycle to expand HSC in murine models
highlights the possibility that the < 20% amino acid shared homology between mouse and
human AhR confers species specific ligand binding.88 These differences between mice
and human AhR could limit the potential of developing therapeutic leads for humans
based on drug screens using murine models. Additionally, improvements in HSC
expansion using AhR as a target for docking of virtual ligands cannot occur since no
crystal structure of human AhR exists. However, there appear to be reports of successful
use of receptor mapping or quantitative structure-activity relationship (QSAR) for lead
development that might be applicable to in silico screens in the future if a crystal
structure is still unavailable.89,90 The discovery of SR1 and its robust expansion of HSCs
has the potential to be an effective clinical therapeutic for successful HSCTs.
Chromatin Modifying Agents: Reestablishing Multipotency
Concomitant with HSC differentiation are epigenetic changes in critical gene
expression networks that arise from global changes in chromatin methylation and
acetylation status.91,92 The hematopoietic genes that are regulated through these networks
ultimately direct progenitor fate and restrict HSC self-renewal potential. Interest in
reversing or mitigating changes in chromatin structure that promote differentiation so that
HSC self-renewal capacity can be preserved has led to the use of hypomethylating agents
as well as histone deacetylase (HDAC) and histone acetyltransferase (HAT) inhibitors.
Of three known HDAC inhibitors including suberoylanilide hydroxamic acid (SAHA),
trichostatin (TSA), and valproic acid (VPA), VPA has been observed to have the most
potent epigenetic reprogramming efficiency.93 The antiepileptic medication VPA was
identified as an HDAC inhibitor that can induce differentiation of cancer cells by
promoting hyperacetylation.94 It has been shown that VPA functions in a dose-dependent
manner to prevent differentiation and promote proliferation of human CD34+ BM cells
when cultured for 7 days.95 Valproic acid induction of proliferation appears to be linked
to down-regulation of the cyclin-dependent kinase (CDK) p21cip-1/waf-1, which regulates
HSC quiescence and entry into the cell cycle.95,96 Additional VPA effects include
inhibition of Gsk-3β, leading to downstream Wnt target gene expression, including
HoxB4.95
Additional efforts to chemically mediate epigenetic programming to facilitate
expansion of HSCs have involved the sequential treatment of cultures with the DNA
methyltranferase inhibitor 5-aza-2’-deoxycytidine (5azaD) followed by TSA.97 Araki et
al. posit that the sequential nature of the treatment is necessary to remove the histone
methylation modifications that sterically restrict access of the deacetylation inhibitor,
TSA. The addition of the compounds to cord blood (CB) CD34+ cells led to a 5-fold to
3.5-fold expansion in CD34+ CD90+ cells that was dependent on the cocktail of cytokines
used within the culture. However, these modest increases were not sustainable past 9
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days of culture and corresponded with a significant decrease in p21 expression,
suggesting that the HSC pool became exhausted.97
Other studies on epigenetic modifiers have resulted in a screen of 92 natural
compounds that led to the isolation of Garcinol (GAR), a plant benzophenone derivative
from the mangosteen family Garcinia indica, which functions as a HAT inhibitor.98 A
synthetic derivative of GAR, Isogarcinol (ISO) led to a 7.4-fold expansion of
CD34+CD38- cells when cultured with cytokines (SCF, TPO) for 7 days. Microarray
analysis of the ISO cultured cells showed upregulation of AMICA1, BTG2, and HLF;
however, upregulation of genes associated with HSC self-renewal (HoxB4, BMI1,
GATA2, Notch-1) was not observed. Possible alternative mechanisms for the HSC
expansion besides epigenetic modifications were suggested to be attributable to
suppressed acetylation of p53 at K382, which leads to reduced targeted DNA binding by
p53.98,99 Using the GAR and ISO observations as an example, it would be prudent to
consider that other chromatin-modifying compounds could also be concurrently affecting
post-translational modifications of proteins that play a role in HSC expansion, like p53.
Consistent with the multiple mechanisms through which chromatin-modifying agents can
function, further work will need to be done to understand and take advantage of their
therapeutic possibilities.
Culture Media Copper Chelation
Copper (Cu) is a dietary trace mineral that is necessary for a fully functional
hematopoietic system. When there is a copper deficiency the resulting effects on HSC
differentiation can manifest in a pathology consisting of anemia, neutropenia, and
thrombocytopenia.100 Efforts to understand the role that inadequate absorption of dietary
Cu plays in hematological abnormalities have led to investigations of how Cu promotes
HSC differentiation and whether limiting Cu availability is beneficial for therapeutic
expansion of HSCs. There isn’t a complete understanding of the role Cu plays in HSC
differentiation, but it is known that retinoic acid, a known promoter of differentiation,
induces uptake of Cu during the early-stage differentiation in human myeloid leukemia
HL-60 cells.101 Additionally, it has been found that cellular-free Cu in cultures promotes
generation of reactive oxygen species (ROS), which leads to HSC exhaustion and can
hinder maintenance of multipotent hematological pools for therapeutic purposes.31,102
Based on these observations, investigators have successfully slowed HSC
differentiation by attenuating copper levels using copper-specific chelators such as
tetraethylenepentamine (TEPA).100,102,103 In one study, TEPA was administered to ex
vivo cultures of purified CD34+ cord blood (CB), which led to a robust enrichment of
early progenitor subpopulations (CD34+CD38- and CD34+Lin-) along with increased
capacity to repopulate NOD/SCID mice.100 These studies set the stage for a phase I/II
clinical trial that was established at MD Anderson Cancer Center to test the effectiveness
of TEPA (StemEx) at expanding a single CB unit that was split into a treated and
untreated arm, then was recombined right before patient administration.103 After culturing
a portion of the CB unit with TEPA and cytokines (Flt-3 ligand, IL-6, and TPO) for 21
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days, the untreated CB arm was infused and administered within 24 hours to each of the
respective ten patients, of whom the average age was 21. Efforts to use a single CB unit
have historically run into the problem of not being able to provide an adult patient with
an adequate supply of TNC for successful engraftment. In this case, the TEPA (StemEx)
treated CB units led to an average TNC expansion of 219-fold and a 6-fold increase in
CD34+ cells over starting numbers, but did not result in faster neutrophil or platelet
reconstitution.103 However, even with the 219-fold expansion, the mean 1.8x107/kg TNCs
administered per adult patient fell below the 3 x 107/kg dose recommended for
engraftment, with higher levels of 5.2x107/kg providing even better success.2,3 Despite
the low TNC dose administered, nine of the ten patients engrafted with a 70% survival
reported at the end of the 180-day study.103 At the conclusion of the StemEx clinical
study, de Lima et al. deemed that treatment of ex vivo cultures with TEPA is feasible and
has led to the establishment of a phase II/III study that will further address safety and
efficacy when expanding a single CB unit for treatment of hematological cancers.
Considering the modest, albeit successful, expansion that StemEx attained, it
would be interesting to see how hypoxic conditions affect ex vivo HSC expansion since
5% CO2 in humidified air (20% O2) was used for the respective study. Reasons for
making such suggestions stem from evidence that administering CuCl2 can stabilize
nuclear Hif-1α under normoxic conditions and that by chelating copper away for upwards
of 3 weeks, while ultimately shown to benefit expansion, could be mitigating known
benefits of hypoxia response element (HRE) mediated gene expression.9,104 Whether
additions of certain stem cell factors, such as TPO, under normoxic conditions can
compensate for hypoxic effects would also need investigation.105 Regardless, it’s possible
that TEPA-induced copper chelation could lead to decreased HIF-1 target gene
expression and negatively impact HSC numbers. While speculative, the effects of
hypoxia would be assumed to lead to decreases in TNC in favor of more LT-HSCs versus
controls. While copper chelation has been shown to be a viable adjuvant to HSC
expansion protocols, further optimizations will be needed if copper chelation is to serve
as an alternative to more robust HSC expansion regimens, such as immobilized Delta-1
and SR1. That being said, copper chelation is most suitable as a potential adjuvant instead
of as a primary HSC expansion therapeutic.
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CHAPTER 6.

IPSC: A POTENTIAL CURE-ALL

The seminal discovery by Taskahashi and Yamanaka that over-expression of key
transcription factors (OCT4, SOX2, KLF4,c-MYC) in fully differentiated somatic cells
can induce embryonic stem (ES) cell-like pluripotency by reprogramming the genomic
methylation signature has ushered in a wave of therapeutic potential for induced
pluripotent stem cell (iPSC) biology.106–108 For hematological disorders, iPSCs offer the
possibility to produce a scalable supply of patient-derived HSCs by successfully
recapitulating an ES-like pluripotent phenotype and inducing directed differentiation of
progenitors.109–111 Recent advances reveal that reprogrammed iPSCs are amenable to
gene-targeting strategies that can be used to treat diseases such as β-thalassemia and
sickle cell anemia.112–115 However, before such methods or iPSC-based HSC expansion
protocols can be used in a clinical setting, a number of issues will first need to be
rectified. Foremost, factor-based reprogrammed cells do not fully recapitulate the
epigenetic state of ES cells despite having similar (95%) global gene expression profiles
and the ability of iPSCs to form all three germ layers: the endoderm, mesoderm, and
ectoderm.116,117 Moreover, the current intractability of iPSCs to be homogenously and
consistently reprogrammed leads to autochthonous lineage-derived methylation
signatures that can foster differentiation that is more congruent with the tissue of
origin.116
Granted, more thorough reprogramming has been achieved through concomitant
use of chromatin-modifying adjuvants such as DNA methyltransferase inhibitor 5-aza-2’deoxycytidine (5-AZA) and the HDAC inhibitor valproic acid.93,116 The drugs appear to
ameliorate incomplete reprogramming by removing latent methylation when used in
conjunction with current reprogramming protocols. Nonetheless, somatic nuclear transfer
was shown to be better than iPSCs at achieving ES-cell-like properties even when treated
with chromatin-modifying compounds. Determining what role these variable methylation
differences play in driving differentiation of different cell types and finding ways to
produce consistent epigenetically stable iPSCs will be imperative to future iPSC-derived
HSC expansion.118
There have also been concerns regarding the ability to recapitulate ES-cell-like
telomeres, which conceivably contributed to early senescence and limited expansion of
iPSC-derived hemangioblasts.119 Conversely, recent reports have shown that iPSCs have
upregulated telomerase expression along with elongated telomeres with ES-like
epigenetic marks.120 It appears that the recalcitrant nature of centromeric and telomeric
DNA to remodeling along with observed iPSC stochastic methylation mechanisms,
highlights the need to further understand what, if any, downstream differentiation effects
exist.117 Additional iPSC concerns center on increasing reprogramming efficiency as well
as discovering stringent clinical strategies for delivering the necessary transcription
factors without utilizing genome-integrating vectors. While genomic safe-harbor
locations have been identified for targeted integration for transgene expression in
thalassemia iPSCs and it is known that exogenous transcription factors are silenced,
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nonetheless the risk of oncogenic integration events arising should be reasonably
mitigated for iPSC-derived HSCTs.114
An interesting use of synthetically modified mRNAs containing 5-methylcytidine
for cytidine and pseudouridine in place of uridine among other structural changes has
achieved an optimized reprogramming efficiency that surpasses .001-3% while also
eliminating the need for vector integrations.121 While synthetic mRNAs presumably offer
a reduced oncogenic profile, daily stoichiometric administration of factors can be
prohibitively time consuming. Other non-integrating efforts have used cell-penetrating
proteins and miRNA, but optimizations to achieve higher reprogramming efficiency are
still necessary.122,123 With emerging higher-efficiency reprogramming conditions
including hypoxia, MEK inhibitor PD0325901, GSK-3 inhibitor CHIR99021,
kenpaullon, and the TGF-B inhibitor RepSox the possibility exists for iPSCs to be
reprogrammed entirely by a cocktail of small molecular therapeutics.124–126
The resounding recognition that iPSCs and the 2012 Nobel Laureates Shinya
Yamanaka and John Gurdon have received for their respective work in 2006 and 1962 is
clear. The potential for iPSCs to revolutionize not just HSC expansion protocols, but also
therapeutics that will benefit from patient-tailored therapeutics is substantial. Moreover,
the vigor with which iPSC issues are being investigated is nothing short of remarkable. It
doesn’t take a great leap of imagination to see how progressing optimizations, along with
our ever-increasing understanding of somatic-to-pluripotent reprogramming, is a
keystone in a looming revolution of tailored cures for hematological diseases. Also, the
inevitable integration of iPSCs with other successful HSC strategies will offer an exciting
supply of clinically relevant HSC expansion opportunities.
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CHAPTER 7.

CONCLUSION

Insofar as multiple signaling pathways can be justifiably separated from one
another through focused pathway research, there comes a time to unite our understanding
of the combination of direct and indirect mechanisms that interact to produce HSC
expansion. Although there is still much that needs to be elucidated, there is evidence that
regulatory pathways can reinforce one another to produce better results than when
isolation of treatments is adopted. These statements should in no way downplay the
challenges of teasing apart complex interactions divided among multiple pathways
because such a thorough understanding will likely necessitate HSC system-wide
investigations to fully comprehend. However, the beginning of such efforts is under way
with the exciting use of induction-coupled mass-spectroscopy (ICP-MS), which permits
many cellular signatures to be analyzed simultaneously in responses to therapeutic
modifications within a single cell.13 The surge in information that such advances in
technology will provide, coupled with automated feeding systems, will facilitate precise
control of potential negative feedback systems when expansion-promoting TFs are
upregulated or HSC epigenetic reprogramming is desired. While still in its relative
infancy with regard to the number of measurements that can be taken concurrently, the
impressive amount of data that has been gathered at this early stage suggests that future
optimizations will provide very detailed snapshots of HSC signaling under varying
conditions.
With the increasing ability to precisely identify the cellular modifications
attributable to HSC regulatory pathways comes the key to synergizing the multitude of
modern clinical strategies in order to expand HSCs for performing HSCTs. It is my view
that not just through solely synergizing complementary pathways together, but also
through a thorough gaining understanding of the indirect and direct negative feedback
effects concordant with upregulation of key regulatory pathways, will the opportunity be
realized to tailor a cocktail of small molecular compounds that can generate clinically
significant quantities of HSCs. It is this author’s opinion that detailed identification of
signaling mechanisms within HSCs will be imperative to extracting the best results
successful for many forms of HSC expansion, as since any efforts to induce constitutive
activation of expansion-promoting genes will likely be mitigated by a concordant
increase in inhibitory regulatory pathways. Once these regulatory pathways are identified,
they can be targeted through small molecular compounds which that will facilitate
achieving the best results possible for HSCT-based therapies.
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